379 related articles for article (PubMed ID: 28172997)
1. Influence of prenatal EGCG treatment and Dyrk1a dosage reduction on craniofacial features associated with Down syndrome.
McElyea SD; Starbuck JM; Tumbleson-Brink DM; Harrington E; Blazek JD; Ghoneima A; Kula K; Roper RJ
Hum Mol Genet; 2016 Nov; 25(22):4856-4869. PubMed ID: 28172997
[TBL] [Abstract][Full Text] [Related]
2. Rescue of the abnormal skeletal phenotype in Ts65Dn Down syndrome mice using genetic and therapeutic modulation of trisomic Dyrk1a.
Blazek JD; Abeysekera I; Li J; Roper RJ
Hum Mol Genet; 2015 Oct; 24(20):5687-96. PubMed ID: 26206885
[TBL] [Abstract][Full Text] [Related]
3. Skeletal Deficits in Male and Female down Syndrome Model Mice Arise Independent of Normalized Dyrk1a Expression in Osteoblasts.
Thomas JR; Sloan K; Cave K; Wallace JM; Roper RJ
Genes (Basel); 2021 Oct; 12(11):. PubMed ID: 34828335
[TBL] [Abstract][Full Text] [Related]
4. Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes.
García-Cerro S; Rueda N; Vidal V; Lantigua S; Martínez-Cué C
Neurobiol Dis; 2017 Oct; 106():76-88. PubMed ID: 28647555
[TBL] [Abstract][Full Text] [Related]
5. Epigallocatechin-3-gallate (EGCG) consumption in the Ts65Dn model of Down syndrome fails to improve behavioral deficits and is detrimental to skeletal phenotypes.
Stringer M; Abeysekera I; Thomas J; LaCombe J; Stancombe K; Stewart RJ; Dria KJ; Wallace JM; Goodlett CR; Roper RJ
Physiol Behav; 2017 Aug; 177():230-241. PubMed ID: 28478033
[TBL] [Abstract][Full Text] [Related]
6. Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans.
De la Torre R; De Sola S; Pons M; Duchon A; de Lagran MM; Farré M; Fitó M; Benejam B; Langohr K; Rodriguez J; Pujadas M; Bizot JC; Cuenca A; Janel N; Catuara S; Covas MI; Blehaut H; Herault Y; Delabar JM; Dierssen M
Mol Nutr Food Res; 2014 Feb; 58(2):278-88. PubMed ID: 24039182
[TBL] [Abstract][Full Text] [Related]
7. Abnormal mineralization of the Ts65Dn Down syndrome mouse appendicular skeleton begins during embryonic development in a Dyrk1a-independent manner.
Blazek JD; Malik AM; Tischbein M; Arbones ML; Moore CS; Roper RJ
Mech Dev; 2015 May; 136():133-42. PubMed ID: 25556111
[TBL] [Abstract][Full Text] [Related]
8. Increased dosage and treatment time of Epigallocatechin-3-gallate (EGCG) negatively affects skeletal parameters in normal mice and Down syndrome mouse models.
Jamal R; LaCombe J; Patel R; Blackwell M; Thomas JR; Sloan K; Wallace JM; Roper RJ
PLoS One; 2022; 17(2):e0264254. PubMed ID: 35196359
[TBL] [Abstract][Full Text] [Related]
9. Normalization of Dyrk1A expression by AAV2/1-shDyrk1A attenuates hippocampal-dependent defects in the Ts65Dn mouse model of Down syndrome.
Altafaj X; Martín ED; Ortiz-Abalia J; Valderrama A; Lao-Peregrín C; Dierssen M; Fillat C
Neurobiol Dis; 2013 Apr; 52():117-27. PubMed ID: 23220201
[TBL] [Abstract][Full Text] [Related]
10. Effect of DYRK1A activity inhibition on development of neuronal progenitors isolated from Ts65Dn mice.
Mazur-Kolecka B; Golabek A; Kida E; Rabe A; Hwang YW; Adayev T; Wegiel J; Flory M; Kaczmarski W; Marchi E; Frackowiak J
J Neurosci Res; 2012 May; 90(5):999-1010. PubMed ID: 22252917
[TBL] [Abstract][Full Text] [Related]
11. Generation of improved human cerebral organoids from single copy DYRK1A knockout induced pluripotent stem cells in trisomy 21: hypothetical solutions for neurodevelopmental models and therapeutic alternatives in down syndrome.
Çağlayan ES
Cell Biol Int; 2016 Dec; 40(12):1256-1270. PubMed ID: 27743462
[TBL] [Abstract][Full Text] [Related]
12. Triplication of DYRK1A causes retinal structural and functional alterations in Down syndrome.
Laguna A; Barallobre MJ; Marchena MÁ; Mateus C; Ramírez E; Martínez-Cue C; Delabar JM; Castelo-Branco M; de la Villa P; Arbonés ML
Hum Mol Genet; 2013 Jul; 22(14):2775-84. PubMed ID: 23512985
[TBL] [Abstract][Full Text] [Related]
13. Commonality in Down and fetal alcohol syndromes.
Solzak JP; Liang Y; Zhou FC; Roper RJ
Birth Defects Res A Clin Mol Teratol; 2013 Apr; 97(4):187-97. PubMed ID: 23554291
[TBL] [Abstract][Full Text] [Related]
14. Trisomy-driven overexpression of DYRK1A kinase in the brain of subjects with Down syndrome.
Dowjat WK; Adayev T; Kuchna I; Nowicki K; Palminiello S; Hwang YW; Wegiel J
Neurosci Lett; 2007 Feb; 413(1):77-81. PubMed ID: 17145134
[TBL] [Abstract][Full Text] [Related]
15. Molecular Rescue of Dyrk1A Overexpression Alterations in Mice with Fontup
Gu Y; Moroy G; Paul JL; Rebillat AS; Dierssen M; de la Torre R; Cieuta-Walti C; Dairou J; Janel N
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32092951
[TBL] [Abstract][Full Text] [Related]
16. Cerebellar alterations in a model of Down syndrome: The role of the Dyrk1A gene.
García-Cerro S; Vidal V; Lantigua S; Berciano MT; Lafarga M; Ramos-Cabrer P; Padro D; Rueda N; Martínez-Cué C
Neurobiol Dis; 2018 Feb; 110():206-217. PubMed ID: 29221819
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of DYRK1A inhibits choline acetyltransferase induction by oleic acid in cellular models of Down syndrome.
Hijazi M; Fillat C; Medina JM; Velasco A
Exp Neurol; 2013 Jan; 239():229-34. PubMed ID: 23124096
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of Dyrk1A is implicated in several cognitive, electrophysiological and neuromorphological alterations found in a mouse model of Down syndrome.
García-Cerro S; Martínez P; Vidal V; Corrales A; Flórez J; Vidal R; Rueda N; Arbonés ML; Martínez-Cué C
PLoS One; 2014; 9(9):e106572. PubMed ID: 25188425
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of Epigallocatechin-3-gallate containing supplements on correcting skeletal defects in a Down syndrome mouse model.
Abeysekera I; Thomas J; Georgiadis TM; Berman AG; Hammond MA; Dria KJ; Wallace JM; Roper RJ
Mol Nutr Food Res; 2016 Apr; 60(4):717-726. PubMed ID: 26748562
[TBL] [Abstract][Full Text] [Related]
20. Sexually dimorphic DYRK1A overexpression on postnatal day 15 in the Ts65Dn mouse model of Down syndrome: Effects of pharmacological targeting on behavioral phenotypes.
Hawley LE; Prochaska F; Stringer M; Goodlett CR; Roper RJ
Pharmacol Biochem Behav; 2022 Jun; 217():173404. PubMed ID: 35576991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
